
Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Immunotherapy: Pathophysiology, Risk Mitigation, and Emerging Strategies
Abstract Anti-amyloid immunotherapies, such as Donanemab and Lecanemab, have demonstrated efficacy in removing amyloid plaques and slowing cognitive decline in early Alzheimer’s disease (AD). However, these therapies are associated with Amyloid-Related Imaging Abnormalities (ARIA), characterized […]